Comparing results metastatic melanoma in PD-1 progressing patients. IOVA, IDRA, ONCS, REPL, CMPI all have results at this year's SITC in this 2L PD-1 refractory melanoma population. We ask an expert to compare trial designs and resultsTicker(s): IOVA, IDRA, ONCS, REPL, CMPI
Hem-Oncologist treating PD-1 refractory patients, up to date on the literature of the differnet approaches (TIL therapy, TLR9, plasmid IL-12 elecrtroporation, oncolytic viruses) and having attended and reviewed recent results from SITC from different companies. Knowledge of regulatory critera for approval important. A recent PI a study in this indication potentially a plus.
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.